Noleus Technologies is developing a novel medical device that accelerates patient recovery after abdominal surgery. It decreases length of stay for patients, saving physicians time and hospitals money. Physicians currently have no available devices to prevent post-operative ileus and bowel edema. The resulting complications lengthen patient length of stay, costing hospitals $2,000 per night. Noleus is a medical device designed to reduce length of stay by preventing post-op ileus and corresponding complications following abdominal surgeries. Patients recover sooner, physicians save time, and hospitals save money.

Malvestio SpA operates as furnishing supplier. Its products include equo linear beds, trend beds, serving tables, wardrobe cabinets, living room tables, armchairs, sideboards, furniture, compositions and sofas. The company is headquartered in Villanova, Italy.

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).

Iodine Software LLC is a machine learning AI technology based company. It provides client based technology solutions. The company was founded by Michael Kadyan in 2010 and is headquartered in Austin, TX.

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

The First People's Hospital of Zhaotong is a Chinese private company located in Zhaotong. The firm provides healthcare services.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

Part of Oracle Corp., Cerner Innovation, Inc. is a company headquartered in the United States specializing in information retrieval services.

Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

Chongqing Changlin Meijie Medical Technology Co., Ltd., established on 2016-04-25, Business scope includes medical equipment,Mechatronics Equipment,Environmental purification equipment,Technology research and development of communication technology equipment,training,transfer,Sales,import and export**[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments].

Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections. The company also focused on the development and commercialization of nitric oxide (NO) formulations for the treatment of lung infections. The revolutionary respiratory-targeted generator and delivery system, LungFit is designed to generate and effectively deliver nitric oxide to intubated and non-intubated patients in both the hospital and the home setting. The LungFit system uses proprietary technology to generate nitric oxide from ambient air and transform the lives of patients with respiratory conditions and severe lung infections. It can deliver nitric oxide either continuously or intermittently with the ability to titrate on demand. The system also satisfies a strong desire to eliminate cylinders from the hospital, providing significant benefits as a result. Beyond was founded in 2011 and is headquartered in Garden City, NY, USA.

Life Spine is focused on providing innovative solutions to address spinal pathology from the occiput to the sacrum. The company's comprehensive product portfolio that centers around fusion and minimally invasive surgeries is driven by patient and surgeon needs. Life Spine is dedicated to improving the quality of life for patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards and the most technologically advanced manufacturing platforms.